Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis
JC Davis, DM van der Heijde, J Braun… - Annals of the …, 2008 - ard.bmj.com
Objective: Evaluate long-term safety and efficacy of etanercept treatment in patients with
ankylosing spondylitis (AS). Methods: Patients with AS who previously participated in a …
ankylosing spondylitis (AS). Methods: Patients with AS who previously participated in a …
Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis.
MC Genovese, JM Bathon, RM Fleischmann… - The Journal of …, 2005 - jrheum.org
OBJECTIVE: To evaluate safety, efficacy, and radiographic progression in patients with early
rheumatoid arthritis (RA) undergoing longterm treatment with etanercept. METHODS …
rheumatoid arthritis (RA) undergoing longterm treatment with etanercept. METHODS …
[PDF][PDF] Brief report: a randomized, double‐blind, parallel‐group, placebo‐controlled, multiple‐dose study to evaluate AMG 557 in patients with systemic lupus …
Objective To evaluate the safety and potential efficacy of AMG 557, a fully human antibody
directed against the inducible T cell costimulator ligand (ICOSL) in patients with systemic …
directed against the inducible T cell costimulator ligand (ICOSL) in patients with systemic …
Baseline factors that influence ASAS 20 response in patients with ankylosing spondylitis treated with etanercept.
JC Davis, DMFM Van der Heijde, M Dougados… - The Journal of …, 2005 - jrheum.org
OBJECTIVE: To examine the baseline demographic and disease characteristics that might
influence improvement as measured by the Assessment in Ankylosing Spondylitis …
influence improvement as measured by the Assessment in Ankylosing Spondylitis …
Preclinical development of AMG 139, a human antibody specifically targeting IL‐23
K Köck, WJ Pan, JM Gow, MJ Horner… - British Journal of …, 2015 - Wiley Online Library
Background and Purpose AMG 139 is a human anti‐IL‐23 antibody currently in a phase II
trial for treating C rohn's disease. To support its clinical development in humans, in vitro …
trial for treating C rohn's disease. To support its clinical development in humans, in vitro …
[HTML][HTML] Safety, tolerability, pharmacokinetics, and efficacy of AMG 403, a human anti-nerve growth factor monoclonal antibody, in two phase I studies with healthy …
JM Gow, WH Tsuji, GJ Williams, D Mytych… - Arthritis research & …, 2015 - Springer
Introduction Nerve growth factor plays a key role in the pathology of osteoarthritis (OA)
related chronic pain. The aim of these studies was to evaluate the safety, tolerability …
related chronic pain. The aim of these studies was to evaluate the safety, tolerability …
Modeling the pharmacokinetic‐pharmacodynamic relationship of the monoclonal anti‐macaque‐IL‐15 antibody Hu714Mu XH u in cynomolgus monkeys
WJ Pan, H Li, JJ Xiao, MJ Horner… - Pharmacology …, 2015 - Wiley Online Library
Hu714Mu XH u is a recombinant chimeric murine‐human monoclonal antibody directed
against interleukin‐15 (IL‐15), a proinflammatory cytokine associated with memory CD 8+ …
against interleukin‐15 (IL‐15), a proinflammatory cytokine associated with memory CD 8+ …
OP0234 Clinical and biologic effects of icosl blockade by amg 557 in subjects with lupus arthritis
Background Blockade of inducible costimulatory ligand (ICOSL) might be a promising
approach for autoimmune diseases such as systemic lupus erythematosus (SLE). We …
approach for autoimmune diseases such as systemic lupus erythematosus (SLE). We …
[CITATION][C] 616-AMG 714 (Anti-IL-15 MAB) halts the progression of aberrant intraepithelial lymphocytes in refractory celiac disease type II (RCD-II): a phase 2a …
C Cellier, G Bouma, T van Gils, S Khater, G Malamut… - Gastroenterology, 2018 - Elsevier
[CITATION][C] Etanercept (Enbrel) in early erosive rheumatoid arthritis (ERA trial): clinical and radiographic data
MC Genovese, RW Martin, RM Fleischmann… - Arthritis Rheum, 2003